Hotel101 Global (HBNB) stock jumps 10% to $8.80 — what to watch before Monday
11 January 2026
1 min read

Hotel101 Global (HBNB) stock jumps 10% to $8.80 — what to watch before Monday

NEW YORK, January 11, 2026, 08:46 (EST) — Market closed.

  • Shares of Hotel101 Global Holdings Corp. ended Friday at $8.80, gaining 10% after reaching a peak of $8.90 during the session.
  • The move unfolded on light volume, leaving the stock vulnerable to sudden, headline-free swings.
  • Traders are focused on whether momentum holds Monday ahead of Tuesday’s U.S. CPI report.

Shares of Hotel101 Global Holdings Corp. jumped 10%, closing at $8.80 on Friday, up 80 cents from the previous close. The stock opened lower at $8.11, with roughly 32,600 shares changing hands. (Hotel 101 Global)

The Nasdaq-listed stock climbed to the upper limit of its 52-week range, reaching $8.90 at its peak. Hotel101’s market cap now sits around $2.06 billion, a figure that, combined with the day’s trading volume, could amplify price fluctuations. (Investing)

This is significant since Hotel101 is still a fresh listing in the U.S., and its stock can swing sharply when trading volume is low. The company, based in Singapore, functions as a subsidiary of Philippine real estate firm DoubleDragon, according to a recent filing. (SEC)

Hotel101 made its Nasdaq debut via a merger with blank-check company JVSPAC Acquisition Corp, valuing the firm at an equity worth of $2.3 billion, Reuters reported. The move marked it as the first Philippine-owned firm to list on the exchange.

With limited analyst coverage, investors are relying heavily on ratings services and official filings for guidance. MarketBeat reported Saturday that Wall Street Zen slapped the stock with a “Sell” rating, while Weiss Ratings kicked off coverage also recommending a sell. (MarketBeat)

Hotel101 describes itself as an asset-light, proptech-focused hospitality platform. Simply put, it earns upfront revenue by selling standardized hotel units and then aims to collect recurring fees through managing and operating those units. (Morningstar)

For now, the tape is calling the shots. The stock is testing recent highs, and even a small surge in buying sends it higher.

Thin liquidity works both ways. A dip in the first hour Monday wouldn’t require heavy selling to take hold, and smaller, newer listings often react swiftly to changes in risk appetite.

Investors are gearing up for a key U.S. data week that frequently shifts rate expectations in the stock market. On Tuesday at 8:30 a.m. ET, the Labor Department will publish the December consumer price index.

Stock Market Today

  • Structure Therapeutics: Can aleniglipron lift the stock in 2026?
    January 11, 2026, 5:26 PM EST. Structure Therapeutics surged after mid-stage data for aleniglipron, a once-daily oral GLP-1 weight-loss candidate. In a 36-week phase 2b study, placebo-adjusted mean weight loss reached 11.3% at the highest dose; higher-dose data suggest up to 15.3%. Tolerability remained within the GLP-1 class norm, with a 10.4% discontinuation rate in the first trial. Management plans a potential phase 3 launch this year while also running a phase 1 for ACCG-2671, an oral amylin-mimetic candidate. Risks loom: regulatory hurdles, and competition from two oral rivals-Wegovy's new oral form and orforglipron-plus a Novo Nordisk pipeline with dual GLP-1/amylin agents. If aleniglipron proves superior, the stock could maintain momentum, but execution risk remains.
Bloom Energy stock heads into Monday after $2.65 billion AEP fuel-cell order sparks fresh analyst split
Previous Story

Bloom Energy stock heads into Monday after $2.65 billion AEP fuel-cell order sparks fresh analyst split

Alphabet (GOOG) stock week ahead: Washington pressure hits Google Play as earnings loom
Next Story

Alphabet (GOOG) stock week ahead: Washington pressure hits Google Play as earnings loom

Go toTop